Abstract
Bacterial vaginosis is associated with severe infectious and inflammatory diseases and reduces the quality of life in women of reproductive age. Its worldwide prevalence is up to 80%. Thus, the development of new effective and safe methods of antimicrobial therapy becomes an urgent problem.
 This article provides a review of current antimicrobial therapies for bacterial vaginosis and evaluates the safety and efficacy of short courses of antimicrobial therapy using combined agents for intravaginal use.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
